3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
1
Lung Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
4
Oxaliplatin
4
zolbetuximab
2
camrelizumab
2
apatinib
2
S 1 (combination)
2
Paclitaxel
2
Nivolumab
2
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
tepotinib
1
relugolix
1
regorafenib
1
lenvatinib
1
durvalumab
1
dabrafenib
1
cemiplimab
1
cabazitaxel
1
alpha-2'-deoxythioguanosine
1
X-Rays
1
Vinorelbine
1
Trifluridine
1
Surveys and Questionnaires
1
Ramucirumab
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Proton Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Adenocarcinoma
×
tepotinib
×
Clear all
NCT02864992
2026-04-13
VISION
EMD Serono
Phase 2
Active not recruiting
337 enrolled
13 charts
2 FDA